These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21382398)

  • 1. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation.
    Dumas JA; Newhouse PA
    Pharmacol Biochem Behav; 2011 Aug; 99(2):254-61. PubMed ID: 21382398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease.
    Robbins TW; McAlonan G; Muir JL; Everitt BJ
    Behav Brain Res; 1997 Feb; 83(1-2):15-23. PubMed ID: 9062655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.
    Lawrence AD; Sahakian BJ
    Neurochem Res; 1998 May; 23(5):787-94. PubMed ID: 9566619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury.
    Arciniegas DB
    Curr Psychiatry Rep; 2003 Oct; 5(5):391-9. PubMed ID: 13678561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the rationale for new treatment strategies in Alzheimer's disease?
    Rogawski MA
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
    Lemière J; Van Gool D; Dom R
    Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.
    Ingram DK; Spangler EL; Iijima S; Ikari H; Kuo H; Greig NH; London ED
    Life Sci; 1994; 55(25-26):2037-49. PubMed ID: 7997063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
    Terry AV; Buccafusco JJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia.
    Dunnett SB; Fibiger HC
    Prog Brain Res; 1993; 98():413-20. PubMed ID: 8248529
    [No Abstract]   [Full Text] [Related]  

  • 10. Bridging neurocognitive aging and disease modification: targeting functional mechanisms of memory impairment.
    Gallagher M; Bakker A; Yassa MA; Stark CE
    Curr Alzheimer Res; 2010 May; 7(3):197-9. PubMed ID: 20088811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction.
    Schliebs R; Rossner S; Bigl V
    Prog Brain Res; 1996; 109():253-64. PubMed ID: 9009714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild cognitive impairment: current research and clinical implications.
    Petersen RC
    Semin Neurol; 2007 Feb; 27(1):22-31. PubMed ID: 17226738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic strategies in the treatment of Alzheimer's disease.
    Davidson M; Stern RG; Bierer LM; Horvath TB; Zemishlani Z; Markofsky R; Mohs RC
    Acta Psychiatr Scand Suppl; 1991; 366():47-51. PubMed ID: 1897375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geniposide ameliorates cognitive deficits by attenuating the cholinergic defect and amyloidosis in middle-aged Alzheimer model mice.
    Zhao C; Zhang H; Li H; Lv C; Liu X; Li Z; Xin W; Wang Y; Zhang W
    Neuropharmacology; 2017 Apr; 116():18-29. PubMed ID: 27940040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A second wind for the cholinergic system in Alzheimer's therapy.
    Douchamps V; Mathis C
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):112-123. PubMed ID: 28240674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
    Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
    [No Abstract]   [Full Text] [Related]  

  • 17. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A short review of alpha activity in cognitive processes and in cognitive impairment.
    Başar E; Güntekin B
    Int J Psychophysiol; 2012 Oct; 86(1):25-38. PubMed ID: 22801250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plurality of patterns of cognitive impairment in normal aging and in dementia].
    Joanette Y; Belleville S; Gely-Nargeot M; Ska B; Valdois S
    Rev Neurol (Paris); 2000 Sep; 156(8-9):759-66. PubMed ID: 10992120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.